Arbutus Biopharma Corporation (ABUS) earnings
ABUS earnings moved a median of +0.32% by the close. Quarterly and annual ABUS reports and results, each read against the price at its own news timestamp. Back to the ABUS overview →
25 measured ABUS earnings events.
Where these ABUS earnings landedvs 23 measured ABUS earnings reactions
| Middle 50% of ABUS earnings reactions | -1.06% to +1.45% |
|---|---|
| Median reaction (to close) | +0.32% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 ABUS earnings events with a measured close landed between -1.06% and +1.45%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -2.20% | +0.00% | |
| Form 10-Q Arbutus Biopharma Corp For: Jun 30 | SEC filing · Form 10-Q | -2.20% | +0.00% | |
| Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | -1.45% | -4.01% | |
| Form 10-Q Arbutus Biopharma Corp For: Mar 31 | SEC filing · Form 10-Q | -1.45% | -4.01% | |
| Form 10-K Arbutus Biopharma Corp For: Dec 31 | SEC filing · Form 10-K | +0.00% | +1.38% | |
| Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -1.88% | — | |
| Form 10-Q Arbutus Biopharma Corp For: Sep 30 | SEC filing · Form 10-Q | -1.88% | — | |
| Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -2.91% | +0.87% | |
| Form 10-Q Arbutus Biopharma Corp For: Jun 30 | SEC filing · Form 10-Q | -2.91% | +0.87% | |
| Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | +0.32% | |
| Form 10-Q Arbutus Biopharma Corp For: Mar 31 | SEC filing · Form 10-Q | -5.43% | -0.32% | |
| Form 10-K Arbutus Biopharma Corp For: Dec 31 | SEC filing · Form 10-K | +0.27% | -2.39% | |
| Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -2.09% | +1.82% | |
| Form 10-Q Arbutus Biopharma Corp For: Sep 30 | SEC filing · Form 10-Q | -1.53% | -4.85% | |
| Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update | Press release | +1.20% | +0.74% | |
| Form 10-Q Arbutus Biopharma Corp For: Jun 30 | SEC filing · Form 10-Q | -0.14% | +1.11% | |
| Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -6.59% | +4.67% | |
| Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update | Press release | +1.06% | -1.86% | |
| Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | +1.51% | |
| Form 10-Q Arbutus Biopharma Corp For: Mar 31 | SEC filing · Form 10-Q | +1.48% | +0.00% | |
| Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update | Press release | +0.00% | -1.80% | |
| Form 10-K Arbutus Biopharma Corp For: Dec 31 | SEC filing · Form 10-K | +0.76% | +4.58% | |
| Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | -2.21% | +2.21% | |
| Form 10-Q Arbutus Biopharma Corp For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update | Press release | +1.18% | +4.12% |
Keep exploring
More ABUS: analyst actions → · SEC filings → · ABUS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kezar Life Sciences, Inc. (KZR) | 192 | +0.14% | 55% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
| BeiGene, Ltd. - American Depositary Shares (BGNE) | 191 | +0.11% | 52% |
| CYTODYN INC (CYDY) | 191 | -0.07% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.